SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG ROVADICITINIB TABLET "ROVADICITINIB (TQ05105)"

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the final analysis of the critical registration clinical trial of the Categroy 1 innovative drug Rovadicitinib Tablet "Rovadicitinib (TQ05105)" developed by the Group for the treatment of moderate and high-risk myelofibrosis (MF) has been completed and has met its primary endpoint. The Group has submitted a new drug marketing application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the People's Republic of China and the application has been accepted.

Rovadicitnib Tablet is a JAK/ROCK inhibitor with new chemical structure self-developed by the Group. It can effectively inhibit the activity of JAK family of kinases and ROCK kinase, and significantly inhibit the phosphorylation levels of STAT3 and STAT5 in cells, thereby inhibiting the conduction of JAK/STAT signaling pathway and in turn exerting anti-tumor activity.

MF is a kind of myeloproliterative neoplasms and a diffuse bone marrow fibrous hyperplasia, including primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF). MF may progress to bone marrow failure or transform into acute leukemia eventually. In September 2023, PMF was included in China's Second Catelogue of Rare Diseases.

Rovadicitnib Tablet is another Categroy 1 innovative drug that the Group has made application for marketing recently. The Group is accelerating a number of clinical research on Rovadicitnib Tablet to fully explore its clinical value. Rovadicitnib Tablet in combination with BET inhibitors or BCL-2 inhibitors is indicated for the treatment of moderate and high-risk MF, and the preliminary clinical results are positive. In addition, Rovadicitnib has also showed apparent efficacy in the treatment of chronic graft-versus-host disease (cGVHD), which is expected to bring a better clinical treatment option for patients with cGVHD.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 15 July 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.